In this post-hoc analysis of ATTRibute-CM, incremental increases in serum TTR levels on Day 28, achieved with acoramidis, may independently predict greater reduction in risks of cardiovascular ...
Redburn Atlantic initiated coverage of BridgeBio with a Buy rating and $50 price target Therapeutic options for patients with transthyretin ...
Clinical researcher Nadine Spring discusses the long-standing lack of diversity in clinical trials and why she's fighting for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback